AOA Dx Files US Patent (No. 63,087427) for the identification of gangliosides as markers for ovarian cancer

AOA DX is pleased to announce it has filed a US Patent (No. 63,087427) for the compositions and methods of ovarian cancer diagnosis. This is an important step in making a cost-effective, accurate and simple liquid-biopsy test for ovarian cancer diagnosis widely available. The application gives 20 years of patent protection for the methods, lasting until at least 2040. The filing protects the intervention of accurate detection of ovarian cancer.

Oriana Zoghbi, CEO of AOA Dx commented, “The claims embodied in this patent application will allow us to proceed with developing and delivering a cost-effective, accurate and simple test for the detection of early-stage ovarian cancer. We strongly believe the technology being developed will provide a best-in-class test and significantly improve the five-year survival rate currently associated with ovarian cancer, the ‘silent killer’.”

“This is the first of many patents we hope to file as part of our overall aim of developing both diagnostic and therapeutic applications that will bring a significant change to women. This news follows a series of recent milestones, including the execution of an exclusive option agreement with Prof. Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University,” says Anna Jeter, CBO at AOA Dx.

About AOA Dx Inc.
AOA Dx Inc (AOA Inc) is a US company, with teams based in Boston, New York and London developing cancer diagnostics in the field of women’s health. AOA Dx Inc, a female led company, is committed to bringing the first accurate early stage liquid biopsy ovarian cancer diagnostic test to market that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers. More information can be found at

Corporate Communications